Upload
delano
View
43
Download
1
Embed Size (px)
DESCRIPTION
Wipo Regional Workshop on Patent Analytics. WIPO & INPI Rio de Janeiro, August 26 a 28, 2013 Samples of Patent Analytics Observatory of Tecnologies - INPI/ Brazil Prof. Adelaide Antunes [email protected]. OBTEC / INPI. Observatory of Technologies - PowerPoint PPT Presentation
Citation preview
OBTEC
Wipo Regional Workshop on Patent Analytics
WIPO & INPI
Rio de Janeiro, August 26 a 28, 2013
Samples of Patent Analytics
Observatory of Tecnologies - INPI/ Brazil
Prof. Adelaide Antunes
OBTEC
OBTEC / INPI
Created in 2010, the Observatory stimulates the interactionbetween Brazilian Office and the several stakeholders of the Brazilian National Innovation System (Universities, Research
Institutes, Finance Organizations, Government Agencies)
Created in 2010, the Observatory stimulates the interactionbetween Brazilian Office and the several stakeholders of the Brazilian National Innovation System (Universities, Research
Institutes, Finance Organizations, Government Agencies)
Observatory of Technologies
Strategic utilizationStrategic utilization of IP System in favor of of IP System in favor of
the economic development.the economic development.
Observatory of Technologies
Strategic utilizationStrategic utilization of IP System in favor of of IP System in favor of
the economic development.the economic development.
OBTEC
Wipo Regional Workshop on Patent Analytics
Observatory of Tecnologies - INPI/ Brazil
It´s necessary
to identify the needs
To develop a Strategy
To search for information
To analyse
To disseminate
Reports
(patents)
Reports
(patents)
University (papers)
INPI (Government)
Industries
Innovation
Economic Development
University (papers)
INPI (Government)
Industries
Innovation
Economic Development
OBTEC
Partnership INPI – OBTEC / FINEP
(Funding Authority for Studies and Projects)
Observatory in the Health Sector
COOPERATION AGREEMENTCOOPERATION AGREEMENT
FINEP –goal: Introduce IP Culture
Brands / Patents
FINEP –goal: Introduce IP Culture
Brands / Patents
OBTEC
EX.: EMSEX.: EMS
Trademarks
Company
Sector Trademarks (applications)
Pending applications
Registered trademarks
Dead trademarks
Frist Application
Latest Application
E M S Drugs 938 237 453 248 Nov., 1963 June, 2012
Priority Country
Patent Documents
Brazil 7Great Britain 3
Patent documents x Priority year
0
1
2
3
4
2003 2004 2005 2006 2007 2008 2009 2010 2011 priority year
pat
ent
do
cum
ents
Patents
Major Generic Drug Company (80% incoming)
Major Generic Drug Company (80% incoming)
OBTEC
STUDIES - DRUGS- FINEP STUDIES - DRUGS- FINEP
Grupo I - Tipo i Capítulo da NCM Medicamentos a base dos fármacos
1 3004.90.68 Atazanavir2 3004.90.69 Ganciclovir3 3004.39.27 Gosserelina4 3004.90.99 Hidroxiuréia5 3004.90.68 Indinavir Sulfato6 3004.31.00 Insulina
7 3004.90.99Isoniazida/Rifampicina/Pirazinamida/
Etambutol8 3004.39.81 Levotiroxina9 3004.90.39 Mitoxantrona
10 3004.90.42 TalidomidaRegra de origem: salto de posição tarifária, exceto do
capítulo 30
OBTEC
GanciclovirGanciclovir
RN: 82410-32-0 IUPAC: 2-amino-1,9-dihydro-9-[[2-hydroxy-1-
(hydroxymethyl)ethoxy]methyl]-6H-Purin-6-one Therapeutic class: antiviral Names and brands 2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]6H-purin-6-one
Biolf 62
BN-B759V
Gansikloviiri
Gansiklovir
Gancyclovir
Gancyklovir
Ganecicilovir
Gansikloviiri
Gansiklovir
HSDB 6512
OBTEC
GanciclovirGanciclovir
Labs Brasil (DEF)
Roche Halex Istar Blausiegel Lafepe Eurofarma
Producers(DWCP) – 38
China - 24
Índia - 4
Alemanha - 3
Estados Unidos - 2
Argentina, Brasil, Canadá, França, Itália – 1
N º Priority documents / Country China - 18
EUA - 5Índia - 5
Escritório Europeu de Patentes - 2 (Itália e França)Espanha e a Itália - 1 depósito cada.
OBTEC
Partnership INPI – OBTEC / FIOCRUZ
Oswaldo Cruz Foundation Science at Service of Life
Observatory in the Health Sector
COOPERATION AGREEMENTCOOPERATION AGREEMENT
OBTEC
Partnership INPI (OBTEC) / FIOCRUZPartnership INPI (OBTEC) / FIOCRUZ
to identify global trends in cancer
subsidize decision-making processes in the Brazilian healthcare sector
Definition of (Brazilian) priorities
Important to know the Patent landscape on cancer drugs
not-patented technologies
patents that have expired
OBTEC
Manual Code Definição B14-H01P Multiple myeloma B14-H01R Oesophageal cancer B14-H01S Ovarian cancer B14-H01T Pancreatic cancer B14-H01U Prostate cancer B14-H01V Rectal cancer B14-H01W Skin melanoma B14-H01X Stomach cancer B14-H01Y Testicular cancer B14-H02 Mutagen, carcinogen B14-H03 Apoptotic B14-H04 Anti-apoptotic B14-H06 Radiosensitizers - Drugs to make tumour cells more
sensitive to radiation therapy B14-S11C Anticancer vaccine B04-G0500E anticancer cell B04-K01S0E cancer cell/cancer cell antigen receptor B04-F02A0E cancer cells, carcinoma (mammalian) B12-G07 Anticancer B04-E02G / B04-E03G
Oncogene
Partnership INPI (OBTEC) / FIOCRUZPartnership INPI (OBTEC) / FIOCRUZ
Manual Code Definição B04-B04C4 Anticancer antibody - B04-B04C8 Cancer antigen B04-F02A Cancer cells/Carcinoma B04-K01S Cancer cell or cancer cell antigen receptor B12-K04A1 Diagnosis of tumours, cancer B14-H01 Anticancer general and other B14-H01A Leukaemia treatment B14-H01B Antiproliferative, inhibitor of cell division, cytostatic B14-H01C Dermatological cancers B14-H01D Endocrine cancers B14-H01D1 Breast cancers B14-H01D2 / B14-H01Z
Thyroid cancers
B14-H01E Gastrointestinal cancers B14-H01E1. Colon cancers B14-H01E2 Oesophageal cancers B14-H01E3 Gall bladder cancers B14-H01E4 Intestinal cancers B14-H01E5 Hepatic cancers B14-H01E6 Pancreatic cancers B14-H01E7 Rectal cancers
Manual Code Definição B14-H01E8 Stomach cancers B14-H01F Genitourinary cancers B14-H01F1 Cervical/uterine cancers B14-H01F2 Kidney cancers B14-H01F3 Ovarian cancers B14-H01F4 Prostate cancers B14-H01F5 Testicular cancers B14-H01F6 Bladder cancers B14-H01G Immunological cancers B14-H01G1 linfoma de hodgkin B14-H01G2 / B14-H01Q
linfoma não-hodkin
B14-H01H Musculoskeletal cancers B14-H01H1 Osteocancers B14-H01H2 Sarcoma B14-H01J Neurological cancers B14-H01J1 Brain tumours B14-H01K Oral and respiratory cancers B14-H01K1 Buccal cavity and pharynx cancers B14-H01K2 Larynx cancers B14-H01K3 Lung cancers B14-H01L Other cancers B14-H01L1 Multiple myelomas B14-H01M Larynx cancer B14-H01N Lung cancer
84.351 patent documents related to cancer drugs
(worldwide)
Derwent Innovations Index
OBTEC
STUDIES
OBTEC
call for papers: International Journal of Molecular Sciences (2013)
Trends in Nanopharmaceutical Patents Trends in Nanopharmaceutical Patents
Case Study
Adelaide Antunes1, Iolanda Fierro1, Rafaela Guerrante1, Flavia Mendes2 and Maria Simone de M. Alencar3
1INPI; 2UFRJ ; 3FIOCRUZ
Scientific journalScientific journal
OBTEC
MethodologyMethodology
Data Base Derwent Innovations Index
Main Advantages
The summaries are full of keywords
The possibility of exporting the patent documents recovered in the search using software (Vantage Point)
The availability of Manual Code related to nanotechnology (classification attributed in the database to all patent documents indexed in it)
Selection of documents that were indexed between 2002 and 2012 in the Derwent database
OBTEC
Manual Codes related to nanotechnology applied to the Manual Codes related to nanotechnology applied to the pharmaceutical sector, and the number of patent documentspharmaceutical sector, and the number of patent documents
Derwent manual code Description Number of patent
documentsB12-M11Q Nanoparticles 2,306
B12-M10A7 Nanotechnology devices 160
B11-C12 Nanotechnology (general) 5,028
B05-U05A Nanotubes, nanorods or nanohorns
100B05-U05B nanofilms
B05-U05C Nanostructures, other than those covered by B05-U05A and B05-U05B
B05-U05 Other carbon containing 3-D structures 44
B05-U04 Carbon plus heteroatom nanotubes 40
B05-U03 Carbon-only nanotubes 615
Removing the patent document that were in more than one of the nine seriesRemoving the patent document that were in more than one of the nine series
toxicity and nanoparticle
nano-imaging agent
nanoparticle for drug delivery
cancer-targeting nanoparticle
Focus on Special Issue “Bioactive Nanoparticle 2012”
Focus on Special Issue “Bioactive Nanoparticle 2012”
OBTEC
ResultsResults
OBTEC
The main patent applicant by area
Total of patents
Entity applying for patents
Toxicity of nanoparticle
Nano-imaging
agent
Nanoparticle for drug delivery
Cancer-targeting
nanoparticle
23 Univ. of California 7 9 7 9
21 Massachusetts Inst. Technology 8 5 7 11
20 General Electric Co 10 20 0 0
16Univ. Nat. Tsing Hua
0 0 12 0
15 GP Medical Inc. 0 0 11 0
12 Univ. Texas System 0 6 5 6
8 Univ. Northwestern 0 0 0 6
8 Elan Pharma Int. Ltd 7 0 0 0
8 Konink Philips Electronics NV 0 8 0 0
7Centre National de La Recherche
Scientifique (CNRS)7 0 0 5
7 Abraxis Bioscience LLC 7 0 0 0
7 Fuji Film Co Ltd 0 0 6 0
6 Brigham & Women’s Hospital Inc. 0 0 0 6
5 Univ. Kyushu 0 0 5 0
OBTEC
MIT Partnerships Auto-Correlation Map
Assignee Codes & Names :empre...
Links >= 0.000000 shown> 0.75 1 (0)0.50 - 0.75 0 (0)0.25 - 0.50 2 (0)< 0.25 7 (0)
UNIV NORTHWESTERNUNIV NORTHWESTERN
UNIV CORNELLUNIV CORNELL
M ITM IT
IM M UNE DISEASE INSTIM M UNE DISEASE INST
HARVARD COLLEGEHARVARD COLLEGE
GEN HOSPITAL CORPGEN HOSPITAL CORP
CHILDRENS HOSPITAL BOSTONCHILDRENS HOSPITAL BOSTON
BRIGHAM &WOM ENS HOSPITAL INCBRIGHAM &WOM ENS HOSPITAL INC MIT
nanoparticles for use in encapsulating a biologically active agent (e.g., polynucleotide)
Advantage is in effectively providing low immunogenicity and toxicity
Universities and HospitalsUniversities and Hospitals
OBTEC
Chapter 5 - The Contribution of Information Science through Intellectual Property to Innovation in the Brazilian Health Sector
Adelaide Maria de Souza Antunes, Flavia Maria Lins Mendes, Suzanne de Oliveira Rodrigues Schumacher,
Luc Quoniam, Jorge Lima de Magalhães
Rethinking The Conceptual Base For New Practical Applications In The Information Value And Quality (IGI
Global 2014 USA)
Rethinking The Conceptual Base For New Practical Applications In The Information Value And Quality (IGI
Global 2014 USA)
OBTEC
Brazil Health System (SUS)
Section 1: Pharmaceuticals industry, made up of six groups
Group 1 – Antivirals (including antiretrovirals)
Group 2 – Neglected Diseases
Group 3 – Chronic non-communicable diseases
Group 4 – Biological pathways
Group 5 – Vaccines and Hemoderivatives
Group 6 – Medications and inputs for the treatment of medical issues resulting from nuclear accidents.
Section 2: Medical devices and healthcare devices in general
OBTEC
Methodology
Database used to access the patent documents: SciFinder Scholar
Search for each drug, using the CAS Registry Number
Informations
patents relating to processes (synthesis and/or formulation);
main Applicants (assignees)
top countries
information about the first patent for the drug, date and respective assignee
patents filed in Brazil
trends over time of patenting
OBTEC
AtorvastatinAtorvastatin
Atorvastatin (CAS RN: 134523-00-5)
114 process patents
84 are for its synthesis
26 for its formulation
4 for its synthesis and formulation
Companies with the most patents (eight each)
Teva Pharmaceuticals Industries
Warner-Lambert Company
First patent
1986 Warner-Lambert Company
Brazil (17 deposits)
Warner Lambert Company (five for synthesis and one for formulation)
Teva Pharmaceuticals Industries (one for formulation and one for synthesis)
Pfizer (synthesis)
0
2
4
6
8
10
12
14
16
18
1986 1989 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Num
ber o
f Pat
ents
Priority Year
Patent Applications Filed for Atorvastatin
OBTEC
Calcitonin Calcitonin
Calcitonin (CAS RN: 9007-12-9) 204 process patents
169 are for its synthesis 28 for its formulation 7 for its synthesis and formulation
Companies with the most patents Armour Pharmaceutical (USA) - 9
First patent 1968 Ciba Ltd (Switzerland)
Brazil (10 patents) 2 for synthesis by Institut Gustave Roussy (France),
0
2
4
6
8
10
12
14
Num
ber o
f Pat
ents
Priority Year
Patent Applications Filed for Calcitonin
OBTEC
III Academic Intelectual Property and Innovation III Academic Intelectual Property and Innovation Development Meeting ( III ENAPID - INPI 2010)Development Meeting ( III ENAPID - INPI 2010)
Key Structures on Synthesis of HIV drugsKey Structures on Synthesis of HIV drugs
Adelaide Maria de Souza Antunes1, Rodrigo José Ávila Cartaxo2, Flavia Maria Lins Mendes2
1INPI; 2UFRJ
Scientific journalScientific journal
OBTEC
Top Applicants: Merck & Co - 15 patentes
Bristol-Myers Squibb Co - 10 patentes
54% em PCT
Technology domination: EUA – 40%
China, Índia e Japan – 41%
19 HIV / SciFinder (CAS/ACS) Busca: RN
19 HIV / SciFinder (CAS/ACS) Busca: RN
OBTEC
Methodology – 19 HIVMethodology – 19 HIV
OBTEC
KEY Chemical Substances Analysis for HIVsKEY Chemical Substances Analysis for HIVs
5-METHYLURIDINE
Me
O
NNH O
O
OHR S
Zidovudine Estavudine
Bristol-Myers (US) and Ajinomoto (JP)
4 routes2 routes
Bristol-Myers, Ajinomoto, Japan Tobacco and China Pharmacy Univ
24 producers :16 China, 2 Canada, 2 USA, 1 Italy, 1 Korea, 1 Slovakia and 1 Rússia
Me
N3
O
NNH O
O
OHRS
S
OBTEC
Thesis
Luiz André Felizardo S. Schlittler (EQ/UFRJ)Advisers: Prof. Nei Pereira Jr./ Profa. Adelaide
Antunes(INPI)
Mapping technological knowlodge of ethanol 2º GenerationMapping technological knowlodge of ethanol 2º Generation
OBTEC
Genetic modification micro-organims
Others compounds production
Enzyme production
Enzymatic hydrolysis
Produção de etanol 2G
Midwest R. Inst.
Univ. Florida
Technological focus
Technological focus
OBTEC
Thesis
Maria Simone de Menezes Alencar (EQ/UFRJ)Adviser: Adelaide Maria de Souza Antunes (INPI)
Technological Foresight applied nanotechnology
Technological Foresight applied nanotechnology
OBTEC
THERMS (strategy)THERMS (strategy)
Base de dados: Derwent Innovation Index
Termos selecionados ESTRATÉGIA DE BUSCA FULLERENES (fullerene*) NANOBELTS ((nanobelt*) or (“nano belt*“)) NANOBIOLOGY ((nanobiolog*) or (“nano biolog*“))
NANOBIOTECHNOLOGY ((nanobiotechnolog*) or (“nano biotechnolog*“) or (bionanotechnolog*) or (“bio nanotechnolog*“))
NANOCATALYST ((nanocatalys*) or (“nano catalys*“)) NANOCOMPOSITE (nanocomposit* or (“nano composit*“)) NANOCORNS ((nanocorn* or “nano corn*“)) NANOCRYSTAL (nanocrystal* or (“nano crystal*“)) NANODROPLETS ((nanodroplet*) or (“nano droplet*“)) NANODRUGS ((nanodrug* or “nano drug“*)) NANOELECTRONICS (nanoelectr* or (“nano electr*“))
OBTEC
ResultsResults
Top countries
Evolução histórica dos países com maior número de depósitos de patentes
3322311343471
537713
268
11791984
997716165929584214
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
EUA JAPÃO CHINA ALEMANHA CORÉIA
2002-2005
1999-2001
1994-1998
OBTEC
AnalysisAnalysis
Classes CIP n patentes Principais usos Posição na nanocadeia de valor
Dispositivos eletrônicos Nanointermediário Dispositivos semicondutores Nanointermediário
H01L–semiconductor devices; electric solid state devices not otherwise provided
2870 Células solares Nanoprodutos Nanotubos de carbono Nanomatéria prima Células combustíveis Nanoprodutos
C01B—non-metallic elements; compounds thereof
2716 Catalisadores Nanointermediário Cancer (tratamento, medicação) Nanoprodutos Cosmeticos Nanoprodutos
A61K—preparations for medical, dental, or toilet purposes
1863 Drogas Nanoprodutos Nanotubos de carbono Nanomatéria prima Dispositivos eletrônicos Nanointermediário
B82B—nano-structures; manufacture or treatment thereof chemistry
1615
Catalisadores Nanointermediário Catalisadores Nanointermediário Células combustíveis Nanoprodutos
B01J —chemical or physical processes, e.g., catalysis, colloid chemistry; their apparatus
1520 Nanotubos de carbono Nanomatéria prima Proteinas Nanomatéria prima Ácidos Nucleicos Nanomatéria prima
G01N—investigating or analyzing materials by determining their chemical or physical properties
1362 Anticorpos Nanomatéria prima Filmes Nanointermediário Revestimentos Nanointermediário
C08K—Use of inorganic or non-macromolecular organic substances as ingredients
1351 Adesivos Nanointermediário Filmes Nanointermediário Revestimentos Nanointermediário
C08L—compositions of macromolecular compounds
1134 Fibras Nanointermediário Field emission display Nanointermediário Nanotubos de carbono Nanomatéria prima
H01J —electric discharge tubes or discharge lamps
1128 Mostradores Nanointermediário
OBTEC
Patenting in The USPatenting in The US
NANOINTERMEDIATES:biosensores, dispositivos
fotovoltaicos e para armazenamento de memória
NANOPRODUCTUS: radiografia industrial, sistemas óticos e de
imagem
NANOPRODUCTUS : com aplicações em
computadores, filmes e automóveis
NANOPRODUCTUS dentais, adesivos e revestimentos dentais e
equipamentos ortodônticos.
CLUSTER 1
OBTEC
Estratégia de Inovação e Tecnologia em Sementes.
Thesis
Rafaela Guerrante (EQ/UFRJ)
advisers: Prof. Nei Pereira Jr. e Profa. Adelaide Maria de Souza Antunes
Innovation Strategy and Technology in SeedsInnovation Strategy and Technology in Seeds
AgricultureAgriculture
OBTEC
Case Study – Monsanto’s patents on GURT (genetic use Case Study – Monsanto’s patents on GURT (genetic use restriction technology)restriction technology)
GURT technology
colloquially known as terminator/traitor technology
causes second generation seeds to be sterile Terminator
the use of an external chemical inducer which turns "on or off" a plant's genetic traits (ex. sterility) Traitor
There are not specific keywords/IPCs to describe GURT technology
1224 Monsanto’s patent documents were retrieved, possibly related to GURT
In order to validate the results and analyze the technologies described in the patents retrieved, a methodology was developed.
OBTEC
“mediated metabolism” OR “inducible”
- “sterile” OR “sterility”
“mediated metabolism” OR
“inducible”
+ “sterile” OR
“sterility”
“sterility” AND/OR “sterile”
“sterility” OR “sterile” OR “mediated metabolism”
OR “inducible”
More Relevant
807 documents
Search Result
1224 documents
Less Relevant
416 documents
Terminator
779 documents
Relevantes
416 documentos
Terminator and Traitor
5 documents
Traitor
23 documents
Reading of CLAIMS and/or
DESCRIPTION
Reading of CLAIMS and/or
DESCRIPTION
Reading of TITLE and/or ABSTRACT
Methodology 1st stepMethodology 1st step
OBTEC
“resistance to”
“increased grain yield”
“increased growth rate”
Filter“sterile”) AND
756 documents
764 docs.
MA
Reading of CLAIMS and DESCRIPTION
DISCARD
“herbicide tolerance”
Filter using AND/OR
“pest resistance”
“tolerance to”
Reading of CLAIMS
and DESCRIPTION
- (“sterility” OR male
Terminator779 documents
9 documents
related to
LE-STERILITY 1 doc.
NOT RELATED
8 documents
765 documents 14 documents
NOT RELATED
DO NOT CONTAIN - (“sterility” OR “sterile”)
AND male
+
Methodology 2st stepMethodology 2st step
OBTEC
Patent and Publications Networks related to Dengue and HPV vaccines: its implications for
policy of innovation in health
Thesis
Priscila Rohem-Santos (IE/UFRJ)
Advisor: Claudia Inês Chamas
OBTEC
Survey design and data sources / AnalysisSurvey design and data sources / AnalysisThe methodology of analysis involves: The search strategy encompasses definition of :
keywords
IPC and Derwent Manual codes
database
I – Identification of Dengue and HPV vaccine patent applications and articles;
II – Creation of clusters according to various indicators such as applicant, priority number, validity (legal status);
III – Claims' analysis of the applications filed in Brazil.
IV – Social Network analysis (coauthorsip/ corinventorship)
OBTEC
Survey design and data sources / AnalysisSurvey design and data sources / Analysis
(3 databases for patents)(3 databases for articles)
Merge results of diferent databases Harmonization of names – ThesaurusEx.: merges/acquisition of pharamautical industries considering the
vaccine sector
(Aventis Pasteur + Pasteur Meriex Connaugth = Aventis Pasteur (Sanofi) + Panacea + Shanta = Sanofi Pasteur (Homma et al, 2011)
Removal of duplicates
Adjacency matrices – correlation of data
OBTEC
RESULTS: HPV articles and patents networksRESULTS: HPV articles and patents networks
BR
OBTEC
RESULTS: Dengue articles and patents RESULTS: Dengue articles and patents networksnetworks
BRFragility of brazilian researchers’ conection
OBTEC
ThanksThanks!!!!!!
Adelaide AntunesAdelaide [email protected]@inpi.gov.br
Elaine ViannaElaine [email protected]@inpi.gov.brBernanrdoNunesBernanrdoNunes
[email protected]@inpi.gov.brCristina D’Urso Cristina D’Urso
[email protected]@inpi.gov.brPriscila RohemPriscila Rohem
[email protected]@inpi.gov.brRafaela GuerranteRafaela [email protected]@inpi.gov.br
[email protected]@inpi.gov.br